The European Commission has granted an extension of the indication for Fiasp (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above).
This complements the previous indication, which covered adults only.
“We are very pleased with the decision of the European Commission to expand the indication of Fiasp, making it available within this younger population,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “With this expanded indication, we hope that adolescents and children who are at least one year old will find in Fiasp a good option in the management of their diabetes.”
Photo of Mads Krogsgaard Thomsen: Novo Nordisk